MX365205B - Preparaciones liofilizadas de melfalán flufenamida. - Google Patents

Preparaciones liofilizadas de melfalán flufenamida.

Info

Publication number
MX365205B
MX365205B MX2015005217A MX2015005217A MX365205B MX 365205 B MX365205 B MX 365205B MX 2015005217 A MX2015005217 A MX 2015005217A MX 2015005217 A MX2015005217 A MX 2015005217A MX 365205 B MX365205 B MX 365205B
Authority
MX
Mexico
Prior art keywords
melphalan flufenamide
lyophilized preparations
directed
pharmaceutical preparations
lyophilized pharmaceutical
Prior art date
Application number
MX2015005217A
Other languages
English (en)
Spanish (es)
Other versions
MX2015005217A (es
Inventor
Jack Spira
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of MX2015005217A publication Critical patent/MX2015005217A/es
Publication of MX365205B publication Critical patent/MX365205B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015005217A 2012-10-26 2013-10-24 Preparaciones liofilizadas de melfalán flufenamida. MX365205B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719184P 2012-10-26 2012-10-26
SE1251211 2012-10-26
PCT/SE2013/051246 WO2014065751A1 (en) 2012-10-26 2013-10-24 Lyophilized preparations of melphalan flufenamide

Publications (2)

Publication Number Publication Date
MX2015005217A MX2015005217A (es) 2015-07-14
MX365205B true MX365205B (es) 2019-05-27

Family

ID=50544986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005217A MX365205B (es) 2012-10-26 2013-10-24 Preparaciones liofilizadas de melfalán flufenamida.

Country Status (18)

Country Link
US (2) US10285946B2 (enExample)
EP (2) EP3628318A1 (enExample)
JP (1) JP6284945B2 (enExample)
KR (1) KR102205592B1 (enExample)
CN (2) CN104994847B (enExample)
AU (1) AU2013335359B2 (enExample)
BR (1) BR112015009280B1 (enExample)
CA (1) CA2889753C (enExample)
CY (1) CY1122483T1 (enExample)
IL (1) IL238398B (enExample)
MX (1) MX365205B (enExample)
NZ (1) NZ708016A (enExample)
PL (1) PL2928463T3 (enExample)
RS (1) RS60068B1 (enExample)
RU (1) RU2643762C2 (enExample)
SI (1) SI2928463T1 (enExample)
SM (1) SMT202000058T1 (enExample)
WO (1) WO2014065751A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
MX2020010031A (es) 2018-03-29 2021-01-08 Airway Therapeutics Inc Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d).
RU2020131642A (ru) 2018-03-29 2022-04-29 Эйрвэй Терапьютикс, Инк. Способы и композиции, содержащие сурфактантный белок d (sp-d)
WO2020079165A1 (en) * 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
WO2020201542A1 (en) 2019-04-03 2020-10-08 Oncopeptides Ab Treatment of al amyloidosis with melflufen
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
US20240307480A1 (en) 2021-07-08 2024-09-19 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
KR102757193B1 (ko) * 2021-10-19 2025-01-21 단국대학교 천안캠퍼스 산학협력단 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US6992207B2 (en) * 2000-06-13 2006-01-31 Oncopeptides Ab Melphalan derivatives and their use as cancer chemotherapeutic drugs
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US7754720B2 (en) * 2006-07-07 2010-07-13 Gilead Sciences, Inc. Pyridazine compound and use thereof
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
CN101584669B (zh) * 2009-06-19 2010-12-29 江苏奥赛康药业有限公司 美法仑冻干粉针剂
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
HRP20201241T1 (hr) 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤

Also Published As

Publication number Publication date
US20150335578A1 (en) 2015-11-26
KR102205592B1 (ko) 2021-01-20
RU2643762C2 (ru) 2018-02-05
JP6284945B2 (ja) 2018-02-28
EP3628318A1 (en) 2020-04-01
WO2014065751A1 (en) 2014-05-01
CY1122483T1 (el) 2021-01-27
AU2013335359B2 (en) 2016-07-21
JP2015535243A (ja) 2015-12-10
EP2928463A1 (en) 2015-10-14
AU2013335359A1 (en) 2015-05-14
BR112015009280A2 (pt) 2017-07-04
CN108685860B (zh) 2022-04-05
SMT202000058T1 (it) 2020-03-13
KR20150070375A (ko) 2015-06-24
MX2015005217A (es) 2015-07-14
CN108685860A (zh) 2018-10-23
US20160271065A1 (en) 2016-09-22
RU2015118581A (ru) 2016-12-20
PL2928463T3 (pl) 2020-06-01
BR112015009280B1 (pt) 2022-05-31
US10285947B2 (en) 2019-05-14
US10285946B2 (en) 2019-05-14
EP2928463A4 (en) 2016-08-31
EP2928463B1 (en) 2019-11-20
CN104994847A (zh) 2015-10-21
CA2889753C (en) 2021-03-02
NZ708016A (en) 2018-02-23
IL238398B (en) 2018-03-29
CN104994847B (zh) 2018-08-10
HK1216501A1 (zh) 2016-11-18
SI2928463T1 (sl) 2020-03-31
IL238398A0 (en) 2015-06-30
RS60068B1 (sr) 2020-05-29
CA2889753A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
GB201118656D0 (en) New compounds
MX366899B (es) Nuevos compuestos.
GB201209613D0 (en) New compounds
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX361585B (es) Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas.
MX349004B (es) Nuevos compuestos.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
IN2013MU03583A (enExample)
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.

Legal Events

Date Code Title Description
FG Grant or registration